Warren Goldenberg

Warren Goldenberg, Senior Counsel at Hahn Loeser’s Cleveland office, is the President and Chief Operating Officer of KeborMed Inc. (www.kebormed.com), a Platform-as-a-Service for cloud connected medical devices. KeborMed is an early revenue company which has a strategic marketing alliance with Ximedica. After more than 30 years as a Partner at Hahn Loeser, Warren became Senior Counsel on September 1, 2021 in connection with closing of KeborMed’s Series Seed financing so that he could devote his substantially full-time efforts to KeborMed.

Warren has more than 35 years of experience in mergers and acquisitions, debt and equity financing, technology transfer and commercialization, clinical trials, financial restructuring, joint ventures and strategic alliances, licensing and distribution agreements, entity formation, shareholder disputes, and stock option and restricted stock plans.

Warren’s law practice has focused on technology and healthcare companies and technology transactions, particularly in the life sciences, information technology and materials industries. He has represented startup companies, universities and Fortune 500 companies. Warren’s experience with technology companies dates back to the early 1990s when he represented U.S. Biochemical Corp., including the spinoff of Ribozyme Pharmaceuticals, which ultimately went public. Warren subsequently led the sale of USB to Amersham Life Sciences.

From 2010 to 2015, Warren served as the part-time CEO of Fluence Therapeutics Inc. in Akron, Ohio. Fluence Therapeutics was a Case Western Reserve University/University Hospitals spin-off company that utilized photodynamic therapy for the treatment of psoriasis and other skin diseases. His accomplishments at Fluence include closing a convertible debt financing round, obtaining Northeast Ohio grant funding and implementing a European commercialization strategy that included the establishment of a subsidiary in Finland and obtaining funding from the Finnish government. He also participated in the European Commission funded Phos-Istos project run by Inserm (the National Institutes of Health of France) and obtained funding from the European Commission.

From 2006 to 2009, Warren served as part-time CEO of CardioInsight Technologies Inc., a Case Western Reserve University/University Hospitals spin-off, in Cleveland. CardioInsight is commercializing electrocardiographic imaging, which is used to guide ablation therapy for atrial fibrillation and other arrhythmias. CardioInsight was ultimately sold to Medtronic in June 2015 for $93 million, plus an earnout. Under Warren’s leadership, the company closed a Series A venture capital financing and raised grant funding from the Global Cardiovascular Innovation Center. It also grew to seven employees, initiated clinical trials and hired a full-time CEO in connection with a Series B financing.

In 1996, Warren formed Imalux Corp. and managed the company until 2001. Imalux commercialized optical coherence tomography imaging technology developed at the Russian Academy of Sciences for catheter-based imaging of epithelial tissues. He obtained grant funding from the State of Ohio and initiated clinical trials at the Cleveland Clinic. In 2001, he recruited a full-time CEO, secured Series A venture capital financing and continued as a board observer representing the Institute of Applied Physics of the Russian Academy of Sciences.